Blog > Editor's Pic > Inovio (INO) soars on positive test news
Share this article:
  • Print
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • NewsVine
  • StumbleUpon
  • Twitter

Inovio (INO) soars on positive test news

Today's Financial News - Posted November 20, 2009

Swine flu vaccine maker Inovio Biomedical Corp. (AMEX:INO) is making up lost ground today with big gains!

by J. Christoph Amberger

INO chartBaltimore, MD TFN: On November 3, I updated Hot Stock Confidential members on our swine flu position Inovio Biomedical Corp. (AMEX:INO) with the fateful words: “So far, INO has disappointed in the short term. But in the medium- to long-term, I see great things for this company. Hold.”

Today, it looks like the medium- to long term has caught up with us. INO is soaring close to 30%.

The company reported that animal studies showed its new DNA-based vaccine was effective in protecting against several strains of influenza, including the strains H1N1 and H5N1, also known respectively as swine and avian flu.

Better late than never. While the swine flu hysteria has cooled down significantly once I demonstrated that, with a good book and an extra pillow for you neck it is eminently survivable, the long-term fall-out of the media-hyped vaccine shortages are predictable: Rather than getting caught short again next year, the U.S. and other governments will be ordering more and earlier next year. That’s good for INO… and good for shareholders.

Now, we’re still down -24% over our official entry price scored on September 3. We’ll continue to hold INO for a while. In case you bought at recent lows, you might start thinking about locking in profits. HSC, however, will continue to cover the stock as an open position!


Next Article: Options Basics: Understanding the terminology

Posted by J. Christoph Amberger · Filed Under Editor's Pic 

Share this article:
  • Print
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • NewsVine
  • StumbleUpon
  • Twitter

 Add to Technorati Favorites | Follow Us on Twitter!

Be the first to leave a reply.

Your comments are welcome